Vermillion’s (Nasdaq: VRML) annual revenue up

Orlando, Fl 3/27/12 (StreetBeat) -- Vermillion Inc. (Nasdaq: VRML) reported a $3.1 million net loss on $868,000 revenue during the fourth quarter ended Dec. 31, versus $4 million on $345,000 revenue during the same three months the year before.

For fiscal 2011, the Austin-based molecular diagnostics company posted a $17.8 million net loss on $1.9 million revenue compared to a $19 million net loss on $1.2 million revenue during the previous fiscal year.

Shares were trading for about $1.78 Tuesday morning.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Vermillion (NASDAQ: VRML) Closes up over 125% as NASDAQ’s Top Percentage Gainer

Chicago, IL 3/7/12 (StreetBeat) - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for molecular diagnostics company, Vermillion, Inc. (NASDAQ: VRML), gaining 125.56% on the day to close at $ 3.00, up 1.67 on over 10 Million shares. The stock continued its rally in after hours trading.

The stock was NASDAQ’s top percentage gainer on a day that NASDAQ closed down over 40 points.

The Company reported news that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has voted to approve an application for a Category 1 CPT code for its OVA1® test, which is designed to help differentiate benign versus malignant ovarian masses.

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Vermillion (Nasdaq: VRML) Receives Category 1 CPT Code Approval for OVA1

Austin, TX 3/6/12 (StreetBeat) -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has voted to approve an application for a Category 1 CPT code for its OVA1® test, which is designed to help differentiate benign versus malignant ovarian masses.

The AMA recently disclosed the new code on its website, which will become effective January 1, 2013.

"This is a major achievement for OVA1 and an endorsement for the unmet clinical need addressed by this important triage test," said Gail S. Page, Vermillion's president and chief executive officer. "This approval was supported by several peer-reviewed publications and positive coverage decisions, including Medicare. The new CPT code is a critical step in advancing the commercialization of OVA1, as we believe it will help streamline claims processing and accelerate further coverage and adoption by private payers."

StreetBeat Disclaimer

Distributed by Viestly